Beyond LKB1 Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment
Abstract
1. Introduction
2. Role of LKB1 in NSCLC Tumor Cell Biology
3. Role of LKB1 Mutations in the Interactions with Tumor Microenvironment (TME)
4. Evidence of LKB1 Impairment in Promoting Lung Tumorigenesis
5. Clinical Significance of LKB1 Alterations in NSCLC
5.1. Prognostic Significance of LKB1 Status
5.2. Predictive Significance of LKB1
6. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Boudeau, J.; Scott, J.W.; Resta, N.; Deak, M.; Kieloch, A.; Komander, D.; Hardie, D.G.; Prescott, A.R.; van Aalten, D.M.F.; Alessi, D.R. Analysis of the LKB1-STRAD-MO25 complex. J. Cell Sci. 2004, 117, 6365–6375. [Google Scholar] [CrossRef] [PubMed]
- Lizcano, J.M.; Göransson, O.; Toth, R.; Deak, M.; Morrice, N.A.; Boudeau, J.; Hawley, S.A.; Udd, L.; Mäkelä, T.P.; Hardie, D.G.; et al. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 2004. [Google Scholar] [CrossRef] [PubMed]
- Shackelford, D.B.; Shaw, R.J. The LKB1-AMPK pathway: Metabolism and growth control in tumour suppression. Nat. Rev. Cancer 2009, 9, 563–575. [Google Scholar] [CrossRef] [PubMed]
- Chavez, J.A.; Roach, W.G.; Keller, S.R.; Lane, W.S.; Lienhard, G.E. Inhibition of GLUT4 translocation by Tbc1d1, a Rab GTPase-activating protein abundant in skeletal muscle, is partially relieved by AMP-activated protein kinase activation. J. Biol. Chem. 2008, 283, 9187–9195. [Google Scholar] [CrossRef]
- Shackelford, D.B.; Abt, E.; Gerken, L.; Vasquez, D.S.; Seki, A.; Leblanc, M.; Wei, L.; Fishbein, M.C.; Czernin, J.; Mischel, P.S.; et al. LKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug Phenformin. Cancer Cell 2013, 23, 143–158. [Google Scholar] [CrossRef]
- Parker, S.J.; Svensson, R.U.; Divakaruni, A.S.; Lefebvre, A.E.; Murphy, A.N.; Shaw, R.J.; Metallo, C.M. LKB1 promotes metabolic flexibility in response to energy stress. Metab. Eng. 2017, 43, 208–217. [Google Scholar] [CrossRef]
- Amos, C.I.; Bali, D.; Thiel, T.J.; Anderson, J.P.; Gourley, I.; Frazier, M.L.; Lynch, P.M.; Luchtefeld, M.A.; Young, A.; McGarrity, T.J.; et al. Fine Mapping of a Genetic Locus for Peutz-Jeghers Syndrome on Chromosome 19p. Cancer Res. 1997, 57, 3653–3656. [Google Scholar]
- Mehenni, H.; Blouin, J.L.; Radhakrishna, U.; Bhardwaj, S.S.; Bhardwaj, K.; Dixit, V.B.; Richards, K.F.; Bermejo-Fenoll, A.; Leal, A.S.; Raval, R.C.; et al. Peutz-Jeghers syndrome: Confirmation of linkage to chromosome 19p13.3 and Identification of a potential second locus, on 19q13.4. Am. J. Hum. Genet. 1997, 61, 1327–1334. [Google Scholar] [CrossRef]
- Hemminki, A.; Markie, D.; Tomlinson, I.; Avizienyte, E.; Roth, S.; Loukola, A.; Bignell, G.; Warren, W.; Aminoff, M.; Höglund, P.; et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998, 391, 184–187. [Google Scholar] [CrossRef]
- Jenne, D.E.; Reimann, H.; Nezu, J.I.; Friedel, W.; Loff, S.; Jeschke, R.; Müller, O.; Back, W.; Zimmer, M. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat. Genet. 1998, 18, 38–43. [Google Scholar] [CrossRef]
- Van Lier, M.G.F.; Westerman, A.M.; Wagner, A.; Looman, C.W.N.; Wilson, J.H.P.; De Rooij, F.W.M.; Lemmens, V.E.P.P.; Kuipers, E.J.; Mathus-Vliegen, E.M.H.; Van Leerdam, M.E. High cancer risk and increased mortality in patients with Peutz—Jeghers syndrome. Gut 2011, 60, 141–147. [Google Scholar] [CrossRef] [PubMed]
- Riegert-Johnson, D.L.; Westra, W.; Roberts, M. High cancer risk and increased mortality in patients with Peutz-Jeghers syndrome. Gut 2012, 61, 322. [Google Scholar] [CrossRef] [PubMed]
- Resta, N.; Pierannunzio, D.; Lenato, G.M.; Stella, A.; Capocaccia, R.; Bagnulo, R.; Lastella, P.; Susca, F.C.; Bozzao, C.; Loconte, D.C.; et al. Cancer risk associated with STK11/LKB1 germline mutations in Peutz-Jeghers syndrome patients: Results of an Italian multicenter study. Dig. Liver Dis. 2013, 45, 606–611. [Google Scholar] [CrossRef] [PubMed]
- Guldberg, P.; Straten, P.T.; Ahrenkiel, V.; Seremet, T.; Kirkin, A.F.; Zeuthen, J. Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma. Oncogene 1999, 18, 1777–1780. [Google Scholar] [CrossRef] [PubMed]
- McCabe, M.T.; Powell, D.R.; Zhou, W.; Vertino, P.M. Homozygous deletion of the STK11/LKB1 locus and the generation of novel fusion transcripts in cervical cancer cells. Cancer Genet. Cytogenet. 2010, 197, 130–141. [Google Scholar] [CrossRef]
- Morton, J.P.; Jamieson, N.B.; Karim, S.A.; Athineos, D.; Ridgway, R.A.; Nixon, C.; McKay, C.J.; Carter, R.; Brunton, V.G.; Frame, M.C.; et al. LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology 2010, 139, 586–597. [Google Scholar] [CrossRef]
- Shen, Z.; Wen, X.F.; Lan, F.; Shen, Z.Z.; Shao, Z.M. The tumor suppressor gene LKB1 is associated with prognosis in human breast carcinoma. Clin. Cancer Res. 2002, 8, 2085–2090. [Google Scholar]
- Sanchez-Cespedes, M.; Parrella, P.; Esteller, M.; Nomoto, S.; Trink, B.; Engles, J.M.; Westra, W.H.; Herman, J.G.; Sidransky, D. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res. 2002, 62, 3659–3662. [Google Scholar]
- Granado-Martínez, P.; Garcia-Ortega, S.; González-Sánchez, E.; McGrail, K.; Selgas, R.; Grueso, J.; Gil, R.; Naldaiz-Gastesi, N.; Rhodes, A.C.; Hernandez-Losa, J.; et al. STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammation. Commun. Biol. 2020, 3, 1–14. [Google Scholar] [CrossRef]
- Presneau, N.; Duhamel, L.A.; Ye, H.; Tirabosco, R.; Flanagan, A.M.; Eskandarpour, M. Post-translational regulation contributes to the loss of LKB1 expression through SIRT1 deacetylase in osteosarcomas. Br. J. Cancer 2017, 117, 398–408. [Google Scholar] [CrossRef]
- Zhang, W.; Li, X.; Song, G.; Luo, D. Prognostic significance of LKB1 promoter methylation in cutaneous malignant melanoma. Oncol. Lett. 2017, 14, 2075–2080. [Google Scholar] [CrossRef] [PubMed]
- Esteller, M.; Avizienyte, E.; Corn, P.G.; Lothe, R.A.; Baylin, S.B.; Aaltonen, L.A.; Herman, J.G. Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome. Oncogene 2000, 19, 164–168. [Google Scholar] [CrossRef] [PubMed]
- Trojan, J.; Brieger, A.; Raedle, J.; Esteller, M.; Zeuzem, S. 5’-CpG island methylation of the LKB1/STK11 promoter and allelic loss at chromosome 19p13.3 in sporadic colorectal cancer. Gut 2000, 47, 272–276. [Google Scholar] [CrossRef] [PubMed]
- Izreig, S.; Samborska, B.; Johnson, R.M.; Sergushichev, A.; Ma, E.H.; Lussier, C.; Loginicheva, E.; Donayo, A.O.; Poffenberger, M.C.; Sagan, S.M.; et al. The miR-17∼92 microRNA Cluster Is a Global Regulator of Tumor Metabolism. Cell Rep. 2016, 16, 1915–1928. [Google Scholar] [CrossRef]
- Jiang, C.; Bi, C.; Jiang, X.; Tian, T.; Huang, X.; Wang, C.; Fernandez, M.R.; Iqbal, J.; Chan, W.C.; McKeithan, T.W.; et al. The miR-17~92 cluster activates mTORC1 in mantle cell lymphoma by targeting multiple regulators in the STK11/AMPK/TSC/mTOR pathway. Br. J. Haematol. 2019, 185, 616–620. [Google Scholar] [CrossRef]
- Zhang, X.; Li, Y.; Qi, P.; Ma, Z. Biology of MiR-17-92 Cluster and Its Progress in Lung Cancer. Int. J. Med. Sci. 2018, 15, 1443–1448. [Google Scholar] [CrossRef]
- Russell, R.C.; Yuan, H.X.; Guan, K.L. Autophagy regulation by nutrient signaling. Cell Res. 2014, 24, 42–57. [Google Scholar] [CrossRef]
- Zulato, E.; Ciccarese, F.; Nardo, G.; Pinazza, M.; Agnusdei, V.; Silic-Benussi, M.; Ciminale, V.; Indraccolo, S. Involvement of NADPH Oxidase 1 in Liver Kinase B1-Mediated Effects on Tumor Angiogenesis and Growth. Front. Oncol. 2018, 8, 195. [Google Scholar] [CrossRef]
- Zhuang, Z.G.; Di, G.H.; Shen, Z.Z.; Ding, J.; Shao, Z.M. Enhanced expression of LKB1 in breast cancer cells attenuates angiogenesis, invasion, and metastatic potential. Mol. Cancer Res. 2006, 4, 843–849. [Google Scholar] [CrossRef]
- Roy, B.C.; Kohno, T.; Iwakawa, R.; Moriguchi, T.; Kiyono, T.; Morishita, K.; Sanchez-Cespedes, M.; Akiyama, T.; Yokota, J. Involvement of LKB1 in epithelial-mesenchymal transition (EMT) of human lung cancer cells. Lung Cancer 2010, 70, 136–145. [Google Scholar] [CrossRef]
- Zhang, S.; Schafer-Hales, K.; Khuri, F.R.; Zhou, W.; Vertino, P.M.; Marcus, A.I. The tumor suppressor LKB1 regulates lung cancer cell polarity by mediating cdc42 recruitment and activity. Cancer Res. 2008, 68, 740–748. [Google Scholar] [CrossRef] [PubMed]
- Goodwin, J.M.; Svensson, R.U.; Lou, H.J.; Winslow, M.M.; Turk, B.E.; Shaw, R.J. An AMPK-independent signaling pathway downstream of the LKB1 tumor suppressor controls snail1 and metastatic potential. Mol. Cell 2014, 55, 436–450. [Google Scholar] [CrossRef] [PubMed]
- Zagórska, A.; Deak, M.; Campbell, D.G.; Banerjee, S.; Hirano, M.; Aizawa, S.; Prescott, A.R.; Alessi, D.R. New roles for the LKB1-NUAK pathway in controlling myosin phosphatase complexes and cell adhesion. Sci. Signal. 2010, 3, ra25. [Google Scholar] [CrossRef] [PubMed]
- Patel, K.; Foretz, M.; Marion, A.; Campbell, D.G.; Gourlay, R.; Boudaba, N.; Tournier, E.; Titchenell, P.; Peggie, M.; Deak, M.; et al. The LKB1-salt-inducible kinase pathway functions as a key gluconeogenic suppressor in the liver. Nat. Commun. 2014, 5, 1–16. [Google Scholar] [CrossRef]
- Cheng, H.; Liu, P.; Wang, Z.C.; Zou, L.; Santiago, S.; Garbitt, V.; Gjoerup, O.V.; Dirk Iglehart, J.; Miron, A.; Richardson, A.L.; et al. SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Sci. Signal. 2009, 2, ra35. [Google Scholar] [CrossRef]
- Murray, C.W.; Brady, J.J.; Tsai, M.K.; Li, C.; Winters, I.P.; Tang, R.; Andrejka, L.; Ma, R.K.; Kunder, C.A.; Chu, P.; et al. An Lkb1-Sik axis suppresses lung tumor growth and controls differentiation. Cancer Discov. 2019, 9, 1590–1605. [Google Scholar] [CrossRef]
- Kaufman, J.M.; Amann, J.M.; Park, K.; Arasada, R.R.; Li, H.; Shyr, Y.; Carbone, D.P. LKB1 loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT. J. Thorac. Oncol. 2014, 9, 794–804. [Google Scholar] [CrossRef]
- Chen, L.; Engel, B.E.; Welsh, E.A.; Yoder, S.J.; Brantley, S.G.; Chen, D.T.; Beg, A.A.; Cao, C.; Kaye, F.J.; Haura, E.B.; et al. A sensitive nano string-based assay to score STK11 (LKB1) pathway disruption in lung adenocarcinoma. J. Thorac. Oncol. 2016, 11, 838–849. [Google Scholar] [CrossRef]
- Carretero, J.; Shimamura, T.; Rikova, K.; Jackson, A.L.; Wilkerson, M.D.; Borgman, C.L.; Buttarazzi, M.S.; Sanofsky, B.A.; McNamara, K.L.; Brandstetter, K.A.; et al. Integrative Genomic and Proteomic Analyses Identify Targets for Lkb1-Deficient Metastatic Lung Tumors. Cancer Cell 2010, 17, 547–559. [Google Scholar] [CrossRef]
- Kaufman, J.M.; Yamada, T.; Park, K.; Timmers, C.D.; Amann, J.M.; Carbone, D.P. A transcriptional signature identifies LKB1 functional status as a novel determinant of MEK sensitivity in lung adenocarcinoma. Cancer Res. 2017, 77, 153–163. [Google Scholar] [CrossRef]
- Skoulidis, F.; Goldberg, M.E.; Greenawalt, D.M.; Hellmann, M.D.; Awad, M.M.; Gainor, J.F.; Schrock, A.B.; Hartmaier, R.J.; Trabucco, S.E.; Gay, L.; et al. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma. Cancer Discov. 2018, 8, 822–835. [Google Scholar] [CrossRef] [PubMed]
- Jure-Kunkel, M.; Wu, S.; Xiao, F.; Abdullah, S.E.; Gao, G.; Englert, J.M.; Hsieh, H.-J.; Mukhopadhyay, P.; Gupta, A.K.; Dennis, P.A.; et al. Somatic STK11/LKB1 mutations to confer resistance to immune checkpoint inhibitors as monotherapy or in combination in advanced NSCLC. J. Clin. Oncol. 2018, 36, 3028. [Google Scholar] [CrossRef]
- Koyama, S.; Akbay, E.A.; Li, Y.Y.; Aref, A.R.; Skoulidis, F.; Herter-Sprie, G.S.; Buczkowski, K.A.; Liu, Y.; Awad, M.M.; Denning, W.L.; et al. STK11/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. Cancer Res. 2016, 76, 999–1008. [Google Scholar] [CrossRef] [PubMed]
- Kitajima, S.; Ivanova, E.; Guo, S.; Yoshida, R.; Campisi, M.; Sundararaman, S.K.; Tange, S.; Mitsuishi, Y.; Thai, T.C.; Masuda, S.; et al. Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer. Cancer Discov. 2019, 9, 34–45. [Google Scholar] [CrossRef] [PubMed]
- Zhu, Y.; An, X.; Zhang, X.; Qiao, Y.; Zheng, T.; Li, X. STING: A master regulator in the cancer-immunity cycle. Mol. Cancer 2019, 18, 1–15. [Google Scholar] [CrossRef]
- Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 2016, 6, 582–598. [Google Scholar] [CrossRef]
- Minciacchi, V.R.; Spinelli, C.; Reis-Sobreiro, M.; Cavallini, L.; You, S.; Zandian, M.; Li, X.; Mishra, R.; Chiarugi, P.; Adam, R.M.; et al. MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer. Cancer Res. 2017, 77, 2306–2317. [Google Scholar] [CrossRef]
- Becker, A.; Thakur, B.K.; Weiss, J.M.; Kim, H.S.; Peinado, H.; Lyden, D. Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis. Cancer Cell 2016, 30, 836–848. [Google Scholar] [CrossRef]
- Song, W.; Yan, D.; Wei, T.; Liu, Q.; Zhou, X.; Liu, J. Tumor-derived extracellular vesicles in angiogenesis. Biomed. Pharmacother. 2018, 102, 1203–1208. [Google Scholar] [CrossRef]
- Ahmadi, M.; Rezaie, J. Tumor cells derived-exosomes as angiogenenic agents: Possible therapeutic implications. J. Transl. Med. 2020, 18, 249. [Google Scholar] [CrossRef]
- Borzi, C.; Calzolari, L.; Ferretti, A.M.; Caleca, L.; Pastorino, U.; Sozzi, G.; Fortunato, O. c-Myc shuttled by tumour-derived extracellular vesicles promotes lung bronchial cell proliferation through miR-19b and miR-92a. Cell Death Dis. 2019, 10, 1–16. [Google Scholar] [CrossRef] [PubMed]
- McAndrews, K.M.; Kalluri, R. Mechanisms associated with biogenesis of exosomes in cancer. Mol. Cancer 2019, 18, 1–11. [Google Scholar] [CrossRef] [PubMed]
- Zhang, C.; Xiao, X.; Chen, M.; Aldharee, H.; Chen, Y.; Long, W. Liver kinase B1 restoration promotes exosome secretion and motility of lung cancer cells. Oncol. Rep. 2018, 39, 376–382. [Google Scholar] [PubMed]
- Sun, R.; Li, J.; Wang, B.; Guo, Y.; Ma, L.; Quan, X.; Chu, Z.; Li, T. Liver kinase B1 promoter CpG island methylation is related to lung cancer and smoking. Int. J. Clin. Exp. Med. 2015, 8, 14070–14074. [Google Scholar] [PubMed]
- Sasai, K.; Sukezane, T.; Yanagita, E.; Nakagawa, H.; Hotta, A.; Itoh, T.; Akagi, T. Oncogene-mediated human lung epithelial cell transformation produces adenocarcinoma phenotypes in vivo. Cancer Res. 2011, 71, 2541–2549. [Google Scholar] [CrossRef]
- Sato, M.; Larsen, J.E.; Lee, W.; Sun, H.; Shames, D.S.; Dalvi, M.P.; Ramirez, R.D.; Tang, H.; DiMaio, J.M.; Gao, B.; et al. Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations. Mol. Cancer Res. 2013, 11, 638–650. [Google Scholar] [CrossRef]
- Ji, H.; Ramsey, M.R.; Hayes, D.N.; Fan, C.; McNamara, K.; Kozlowski, P.; Torrice, C.; Wu, M.C.; Shimamura, T.; Perera, S.A.; et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007, 448, 807–810. [Google Scholar] [CrossRef]
- Jackson, E.L.; Willis, N.; Mercer, K.; Bronson, R.T.; Crowley, D.; Montoya, R.; Jacks, T.; Tuveson, D.A. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001, 15, 3243–3248. [Google Scholar] [CrossRef]
- Calles, A.; Sholl, L.M.; Rodig, S.J.; Pelton, A.K.; Hornick, J.L.; Butaney, M.; Lydon, C.; Dahlberg, S.E.; Oxnard, G.R.; Jackman, D.M.; et al. Immunohistochemical Loss of LKB1 Is a biomarker for more aggressive biology inKRAS-mutant lung Adenocarcinoma. Clin. Cancer Res. 2015, 21, 2851–2860. [Google Scholar] [CrossRef]
- Moro, M.; Caiola, E.; Ganzinelli, M.; Zulato, E.; Rulli, E.; Marabese, M.; Centonze, G.; Busico, A.; Pastorino, U.; De Braud, F.G.; et al. Metformin enhances cisplatin-induced apoptosis and prevents resistance to cisplatin in co-mutated KRAS/LKB1 Non-Small Cell Lung Cancer (NSCLC). J. Thorac. Oncol. Non-Small Cell Lung Cancer 2018, 13, 1692–1704. [Google Scholar] [CrossRef]
- Skoulidis, F.; Arbour, K.C.; Hellmann, M.D.; Patil, P.D.; Marmarelis, M.E.; Awad, M.M.; Murray, J.C.; Hellyer, J.; Gainor, J.F.; Dimou, A.; et al. Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer. J. Clin. Oncol. 2019, 37, 102. [Google Scholar] [CrossRef]
- Shire, N.J.; Klein, A.B.; Golozar, A.; Collins, J.M.; Fraeman, K.H.; Nordstrom, B.L.; McEwen, R.; Hembrough, T.; Rizvi, N.A. STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world. PLoS ONE 2020, 15, e0238358. [Google Scholar] [CrossRef] [PubMed]
- Rizvi, N.; Cho, B.C.; Reinmuth, N.; Lee, K.H.; Luft, A.; Ahn, M.; Papadimitrakopoulou, V.; Heymach, J.; Scheuring, U.; Higgs, B.; et al. OA04.07 Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial. J. Thorac. Oncol. 2019, 14, S217. [Google Scholar] [CrossRef]
- Gadgeel, S.M.; Rodriguez-Abreu, D.; Felip, E.F.; Esteban, E.; Speranza, G.; Reck, M.; Hui, R.; Boyer, M.; Garon, E.B.; Horinouchi, H.; et al. LB-397/21: Pembrolizumab Plus Pemetrexed and Platinum vs. Placebo Plus Pemetrexed and Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Analysis of KEYNOTE-189 by STK11 and KEAP1 status; AACR Abstract; American Association for Cancer Research: Philadelphia, PA, USA, 2020. [Google Scholar] [CrossRef]
- Tzu, S. The Art of War; Simon & Schuster: New York, NY, USA, 2020. [Google Scholar]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Borzi, C.; Galli, G.; Ganzinelli, M.; Signorelli, D.; Vernieri, C.; Garassino, M.C.; Sozzi, G.; Moro, M. Beyond LKB1 Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment. Pharmaceuticals 2020, 13, 385. https://doi.org/10.3390/ph13110385
Borzi C, Galli G, Ganzinelli M, Signorelli D, Vernieri C, Garassino MC, Sozzi G, Moro M. Beyond LKB1 Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment. Pharmaceuticals. 2020; 13(11):385. https://doi.org/10.3390/ph13110385
Chicago/Turabian StyleBorzi, Cristina, Giulia Galli, Monica Ganzinelli, Diego Signorelli, Claudio Vernieri, Marina Chiara Garassino, Gabriella Sozzi, and Massimo Moro. 2020. "Beyond LKB1 Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment" Pharmaceuticals 13, no. 11: 385. https://doi.org/10.3390/ph13110385
APA StyleBorzi, C., Galli, G., Ganzinelli, M., Signorelli, D., Vernieri, C., Garassino, M. C., Sozzi, G., & Moro, M. (2020). Beyond LKB1 Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment. Pharmaceuticals, 13(11), 385. https://doi.org/10.3390/ph13110385